21 results about "Uvea" patented technology

Disclosed are multi-peptide compositions and / or methods of use of the multi-peptide compositions for patients with resected (or definitively treated) high-risk uveal melanoma. Pharmaceutically acceptable embodiments administered to patients may raise an immune system response against uveal melanoma cells, leading to a decrease in uveal melanoma cell number. Further embodiments may take the form of an adjuvant therapy or a neoadjuvant therapy, as monotherapy or in combination with other therapies.

The invention belongs to the technical field of biological medicine, and particularly discloses application of a small molecule compound DRP (Dalicyclic Polymorphism)-104 in preparation of a medicine for treating uveal melanoma. The molecular formula of the DPR-104 is CHNO; an in-vitro experiment proves that the small molecular compound DPR-104 can effectively kill uveal melanoma cells, specifically, proliferation of the uveal melanoma cells is inhibited in an in-vitro concentration-dependent manner, and apoptosis of tumor cells is promoted; animal experiments prove that DPR-104 can effectively kill uveal melanoma in vivo and enhance the effect of uveal melanoma radiotherapy. On the basis, the invention provides a brand-new treatment medicine for uveal melanoma, the treatment effect can be effectively improved, and the life of a patient can be prolonged.

Metastatic uveal melanomas are highly resistant to all existing treatments. To identify actionable vulnerabilities, the inventors conducted a CRISPR-Cas9 knockout screen using a library composed of chromatin remodelers. They revealed that the histone H3 methyltransferase SETDB1 plays a critical role in metastatic uveal melanoma cell proliferation and survival. Functionally, SETDB1 knockdown triggers decreased expression of genes related to replication and cell cycle and promotes growth arrest associated with increased markers for DNA damage and senescence entry. Using pre-clinical model, they further demonstrated that anti-SETDB1 therapy tumor growth in vivo. The inventors identify SETDB1 as a new relevant therapeutic target for the treatment of metastatic uveal melanomas. The present invention relates to a method for treating uveal melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of SETDB1 inhibitor.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an ITGA6 inhibitor in preparation of a medicine for treating uveal melanoma. By integrating bioinformatics analysis of databases of TCGA, GTEx, CPTAC and the like, the invention systematically reveals that the ITGA6 has high specific expression in uveal melanoma and is significantly related to poor prognosis of a patient for the first time. In-vitro experiments prove that by knocking down ITGA6, proliferation, migration, invasion and colony forming ability of UVM cells can be effectively inhibited. According to the invention, small molecular compounds such as 4.5-diphenyl-1H-imidazole, MS-275, W-13 and the like and siRNA (small interfering Ribonucleic Acid) targeting ITGA6 are screened out to be used as effective inhibitors, and specific drug dosage forms such as intraocular injection and the like are provided. In addition, the ITGA6 inhibitor can be used in combination with a PD-1 / PD-L1 inhibitor, a CTLA-4 inhibitor or a chemotherapeutic drug to generate a synergistic anti-tumor effect. Mechanism research shows that ITGA6 promotes UVM progress by regulating a signal channel and a tumor immune microenvironment. The invention provides a new targeted treatment strategy for uveal melanoma, and has important clinical application value.

In particular, the present invention provides a fusion protein useful in the treatment and prevention of cancer, especially melanoma, and especially cutaneous melanoma and uveal melanoma. [Solution] A fusion protein is provided comprising six antigenic polypeptides (a) to (f), wherein each antigenic polypeptide (a) to (f) has an immunogenic fragment of a specific amino acid sequence or a variant thereof.

Provided herein is a neoadjuvant therapy and / or adjuvant therapy for the treatment of uveal melanoma, inter alia, ocular tumors in uveal melanoma to reduce the incidence of metastasis and / or enucleation and / or preserving eye function.

The invention relates to the inhibition of expression of mutant G protein subunit alpha q (GNAQ) or a mutant G protein subunit alpha 11 (GNA11) gene using siRNA, shRNA, gene editing systems, and compositions thereof. The invention further relates to methods of treating uveal melanoma using the siRNA, shRNA, gene editing systems, and compositions thereof.

The present invention relates to an antibody-drug conjugate (ADC) comprising a bispecific antigen-binding molecule and a cytotoxin, wherein the bispecific antigen-binding molecule comprises: a first antigen-binding domain (D1); and a second antigen-binding domain (D2); wherein D1 binds specifically to a first human MET epitope; wherein D2 binds specifically to a second human MET epitope; wherein D1 comprises the amino acid sequence of SEQ ID NO: 60; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 62; an HCDR3 comprising the amino acid sequence of SEQ ID NO: 64; a light chain complementarity-determining region (LCDR1) comprising the amino acid sequence of SEQ ID NO: 140; and an LCDR2 comprising the amino acid sequence of SEQ ID NO: 142. and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 144;and wherein D2 comprises: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 84; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 86; an HCDR3 comprising the amino acid sequence of SEQ ID NO: 88; an LCDR1 comprising the amino acid sequence of SEQ ID NO: 140; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 142; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 144; for use in the treatment, reduction of tumor growth and / or regression of c-MET-expressing uveal melanoma in a subject in need, wherein the ADC formulated for administration to the subject results in the destruction of c-Met-expressing uveal melanoma cells;

The invention relates to the technical field of tumor early warning, and discloses an LAMA-IL-6-JAK-STAT3 axis-targeted uveal melanoma micro-metastasis early warning and immune escape blocking system, which comprises a micro-metastasis early warning module, a cooperative control module and an immune escape blocking module, the system executes the following steps: S1, target anchoring and sample collection: the micro-transfer early warning module specifically binds LAMA protein, IL-6 cell factors and JAK / STAT3 kinase in a sample through a targeting probe, and collects uveal melanoma nidus tissue cells and a peripheral blood sample to complete target anchoring. In the system, an LAMA-IL-6-JAK-STAT3 axis is used as a specific action target, an LAMA antagonist, an IL-6 receptor inhibitor and a JAK kinase inhibitor in the composite targeting preparation respectively and accurately act on key nodes of a signal axis, and down-regulation of STAT3 activity is realized through stepped regulation, so that non-specific damage of traditional treatment to normal cells is avoided, toxic and side effects of intraocular tissues are reduced, and the treatment effect is good. The local diagnosis and treatment requirements of uveal melanoma are particularly met.

These inventions disclose a non-invasive diagnostic system for intraocular tumor detection using AI-assisted Raman spectroscopy. A monochromatic laser source directs excitation light into intraocular tissue, generating Raman-scattered light that is collected and processed by a spectrometer equipped with a charge-coupled device (CCD). The resulting spectral data is analyzed by an artificial intelligence (AI) processor trained to detect spectral features associated with intraocular tumors. The system identifies known and newly discovered biomarkers, enabling real-time classification, risk stratification, and longitudinal monitoring of tumor evolution. An integrated user interface displays diagnostic results for clinical decision-making. The system supports dynamic updates to the AI model and biomarker database post-deployment, providing adaptive learning capabilities that extend its utility over time. Applications include detection of uveal melanoma, retinoblastoma, metastatic tumors, and related ocular pathologies. The inventions offer high sensitivity and specificity through multi-modal integration, advanced signal processing, and adaptable machine learning frameworks.

The present invention relates to a method for treating uveal melanoma liver metastasis in a human subject. The method comprises administering to the subject a therapeutically effective combination of one or more checkpoint inhibitors and a toll-like receptor 9 (TLR9) agonist having the following structure: 5 '-TCG AAC GTT CGA ACG TTC GAA CGT TCG AAT-3' (SEQ ID NO: 1). The one or more checkpoint inhibitors are systemically administered to the subject and the TLR9 agonist is locally administered to the liver of the subject by means of hepatic arterial infusion at a dose sufficient to provide a therapeutically effective concentration in the liver when combined with the checkpoint inhibitor.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a WZB117 nano preparation and a preparation method thereof. In the treatment of uveal melanoma, there is a lack of effective treatment scheme. The application provides a novel ophthalmic preparation and a preparation method thereof, and utilizes hemoglobin and dopamine to simultaneously carry a glucose transporter 1 (Glut1) inhibitor WZB117 and copper ions. The nano preparation can form a positive feedback cycle through a copper death-induced active oxygen burst and an antioxidant system collapse caused by WZB117 double-sulfur death, so as to accelerate tumor cell death.

The invention discloses a biomarker for predicting liver metastasis of BAP1 mutant uveal melanoma and application of the biomarker, and belongs to the technical field of medicines. The invention provides an application of S100A6 as a biomarker for predicting liver metastasis of BAP1 mutant uveal melanoma, and the S100A6 plays an important role in occurrence and development of the uveal melanoma, also regulates the metastasis capability of the BAP1 mutant uveal melanoma, and plays an important regulation function in the liver metastasis process. The invention further provides application of the S100A6 as a drug action target to development of drugs for treating liver metastasis of uveal melanoma, especially liver metastasis of BAP1 mutant uveal melanoma, and liver metastasis is inhibited by inhibiting or knocking down the S100A6 gene. The invention provides a new strategy for clinical treatment of liver metastasis of BAP1 mutant uveal melanoma.

The present invention relates to a bioswitchable, embedded miRNA-loaded tetrahedral framework nucleic acid, and a preparation method therefor and the use thereof. In the present invention, miRNA is embedded into a tetrahedral framework nucleic acid (tFNA), and a ribonucleotide is extended at the end of each miRNA strand as a biological switch. Such enzyme-responsive biological switches can be triggered by intracellular RNase H to realize the disassembly of a three-dimensional structure. Moreover, the miRNA comprises a toehold-mediated strand displacement domain, which facilitates the binding of miRNA to an intracellular target, thereby achieving specific cell recognition. The miRNA delivery platform provided by the present invention can effectively treat tumors such as uveal melanoma, and diseases such as acute liver injuries and acute kidney injuries.

The present application encompasses TCRs and combinations of TCRs for treatment of melanoma (e.g., cutaneous melanoma, uveal melanoma, or advanced melanoma), non-small cell lung cancer (NSCLC), head and neck cancer (e.g., non-nasopharyngeal head and neck cancer), sarcoma, thyroid cancer, cervical cancer, ovarian cancer, anal cancer, genital cancer, or anogenital cancer. Due at least in part to the heterogeneity of solid tumor cells, therapies used to treat solid tumors often result in a partial response. The present disclosure includes, among other things, multiplexing of TCRs in a single therapy or therapeutic regimen of engineered T cells.

In particular, polypeptides and nucleic acids encoding the same useful for the treatment, prevention and diagnosis of cancer, in particular melanoma, especially cutaneous melanoma and uveal melanoma are disclosed.

Provided herein is a pharmaceutical composition comprising a PKC inhibitor for use in the treatment of cancer, such as uveal melanoma.

The invention belongs to the technical field of biological medicines, and particularly discloses application of a small molecule compound SHIN1 in preparation of a medicine for treating uveal melanoma (UM). Cell experiments prove that the small molecule compound SHIN1 can significantly inhibit the proliferation and clone formation ability of UM cells, and animal experiments prove that the SHIN1 can inhibit UM tumor formation in vivo. On the basis, a new field of application of SHIN1 to UM treatment is developed, a new treatment medicine is provided for UM, the awkward situation that no medicine can be used for UM clinically is solved, the life of a patient is prolonged, and the life quality of the patient is improved.